Key Developments: Abbott Laboratories (ABT)

ABT on New York Consolidated

44.86USD
18 Dec 2014
Price Change (% chg)

$0.60 (+1.36%)
Prev Close
$44.26
Open
$44.71
Day's High
$45.38
Day's Low
$44.44
Volume
1,644,141
Avg. Vol
5,122,695
52-wk High
$46.10
52-wk Low
$35.65

Search Stocks

Latest Key Developments (Source: Significant Developments)

Abbott Laboratories announces increase in quarterly dividend
Friday, 12 Dec 2014 11:18am EST 

Abbott Laboratories:Increases the company's quarterly common dividend to $0.24 per share from $0.22 per share.Payable Feb. 13, 2015, to shareholders of record on Jan. 15, 2015.  Full Article

Abbott Laboratories completes acquisition of Veropharm
Friday, 12 Dec 2014 12:03am EST 

Abbott Laboratories:Acquires control of Veropharm, a Russian pharmaceutical manufacturer.Through this acquisition, Abbott establishes a manufacturing footprint in Russia through Veropharm's production facilities, which include a new manufacturing facility currently under construction.Acquired control of Veropharm for 16.7 bln rubles (or about US$305 mln) through its purchase of Limited Liability Company Garden Hills, the holding company that currently owns about 98 pct of Veropharm.  Full Article

Abbott Laboratories to purchase Topera Inc
Wednesday, 29 Oct 2014 09:30am EDT 

Abbott Laboratories:Entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation.Completion of the Topera acquisition is subject to customary closing conditions, including antitrust clearance.Expected to close in the fourth quarter of this year.  Full Article

Abbott Laboratories narrows FY 2014 EPS outlook to a range above analysts' estimates; gives Q4 2014 EPS outlook in line with analysts' estimates
Wednesday, 22 Oct 2014 07:32am EDT 

Abbott Laboratories:Says it is raising the mid-point and narrowing its FY 2014 earnings-per-share guidance, excluding specified items, to $2.25 to $2.27 from $2.19 to $2.29, representing double-digit growth.Says including net specified items, projected earnings per share under GAAP would be $1.22 to $1.24 for FY 2014, including results from both continuing and discontinued operations.Expects Q4 2014 earnings-per-share guidance, excluding specified items, of $0.68 to $0.70, representing double-digit growth.Expects Q4 2014 including specified items, projected earnings-per-share under GAAP would be $0.32 to $0.34.FY 2014 EPS of $2.24 - Thomson Reuters I/B/E/S.Q4 2014 EPS of $0.70 - Thomson Reuters I/B/E/S.  Full Article

Abbott completes acquisition of CFR Pharmaceuticals
Friday, 26 Sep 2014 09:00am EDT 

Abbott Laboratories:Says has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding company's presence in fast-growing markets.Through purchase of controlling interest and tender offers described below, Abbott indirectly acquired more than 99 pct of CFR's ordinary shares for about $2.9 bln.  Full Article

Abbott Laboratories II study shows abbott's dissolving heart device comparable to Heart stent
Sunday, 14 Sep 2014 03:00pm EDT 

Abbott Laboratories:Announces positive one year clinical results from ABSORB II, the prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's metallic XIENCE family of DES.Says the trial, conducted primarily in Europe, included 501 people with coronary artery disease (CAD), the most common form of heart disease.  Full Article

Abbott Laboratories announces new $3 bln share repurchase program, declares dividend
Thursday, 11 Sep 2014 01:39pm EDT 

Abbott Laboratories:Authorizes the repurchase of up to $3 billion of the corporation's common shares.Purchases may be made from time to time as market conditions warrant and subject to regulatory considerations.Declares quarterly common dividend of $0.22 per share.Cash dividend is payable Nov. 15, to shareholders of record at the close of business on Oct. 15.  Full Article

Abbott receives CE mark for FreeStyle Libre
Wednesday, 3 Sep 2014 09:30am EDT 

Abbott Laboratories:Receives CE Mark (Conformite Europeenne) for its FreeStyle Libre Flash Glucose Monitoring System, a new glucose sensing technology for people with diabetes.The system eliminates the need for routine finger pricks1, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.  Full Article

Abbott Laboratories commences tender offer for all outstanding ordinary shares and american depositary shares of CFR Pharmaceuticals S.A
Monday, 25 Aug 2014 09:00am EDT 

Abbott Laboratories:Announced that Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation (ALH) subsidiary has commenced tender offer (U.S. Offer).Says offer in which it is offering to purchase from U.S. holders only, up to 100 pct of outstanding ordinary, nominative, no par value shares of CFR Pharmaceuticals S.A. (CFR) Chilean corporation and from all holders, wherever resident, up to 100 pct of outstanding American Depositary Shares.Tender Offer for shares and ADS issued dated as of May 9, 2011, between CFR and The Bank of New York Mellon, as Depositary.Says each of which represents 100 ordinary shares, in each case, on terms and subject to conditions set forth in U.S. Offer to Purchase, dated Aug. 25, 2014, and in related ordinary share acceptance letter and ADS Letter of Transmittal, as applicable.Says U.S. Offer will expire on Sept. 23 unless U.S. Offer is extended.  Full Article

Abbott Laboratories declares 362nd quarterly dividend
Wednesday, 16 Jul 2014 07:45am EDT 

Abbott Laboratories:Declares quarterly dividend of $0.22 per share.Payable on Aug. 15 to shareholders of record at the close of business on July 15.  Full Article

BRIEF-Abbott completes acquisition of Veropharm

* Says Abbott announced that it has acquired control of the company

Search Stocks